BiotechTube

NNZ-2591

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

Sep 1, 2023 → Jun 30, 2025

NCT ID
NCT05879614

About NNZ-2591

NNZ-2591 is a phase 2 stage product being developed by Neuren Pharmaceuticals for Prader-Willi Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05879614. Target conditions include Prader-Willi Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT05879614Phase 2Withdrawn
NCT05025332Phase 2Completed
NCT05025241Phase 2Completed
NCT05011851Phase 2Completed

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors
ProductCompanyStageHype Score
Octreotide + PlaceboNovartisPre-clinical
23
Norditropin SimpleXxNovo NordiskPre-clinical
22
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3
76
Setmelanotide + PlaceboRhythm PharmaceuticalsPhase 2
49
SetmelanotideRhythm PharmaceuticalsPhase 2
49
RGH-706 + PlaceboRichter GedeonPhase 2
49
CarbetocinAcadia PharmaceuticalsPhase 3
72
Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3
72
DCCRSoleno TherapeuticsPhase 3
72
DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
PitolisantHarmony BiosciencesPhase 3
72
Pitolisant tabletHarmony BiosciencesPhase 3
72
Pitolisant oral tablets + Placebo oral tabletHarmony BiosciencesPhase 2
47
DCCRSoleno TherapeuticsPhase 3
72
VYKAT XRSoleno TherapeuticsPre-clinical
18
DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3
72
BMB-101 + PlaceboBright Minds BiosciencesPhase 2
47
ARD-101Aardvark TherapeuticsPhase 2
44

Other Products from Neuren Pharmaceuticals

NNZ-2591 + PlaceboPhase 3
72
NNZ-2591Phase 2
47
NNZ-2566 + PlaceboPhase 2
47
NNZ-2566 + PlaceboPhase 2
47
NNZ-2566 + PlaceboPhase 2
47